FSMC total trajectories according to FSMC total starting values, n (%) | |||||
No | Low | Mild | Moderate | Severe | |
N (%) | 288 (18.1) | 382 (24.1) | 340 (21.4) | 320 (20.2) | 257 (16.2) |
Age at DMT start, years | |||||
18–29 | 99 (34.4) | 140 (36.6) | 100 (29.4) | 80 (25.0) | 65 (25.3) |
30–44 | 144 (50.0) | 167 (43.7) | 160 (47.1) | 161 (50.3) | 114 (44.4) |
>44 | 45 (15.6) | 75 (19.6) | 80 (23.5) | 79 (24.7) | 78 (30.4) |
Female | 162 (56.3) | 254 (66.5) | 245 (72.1) | 240 (75.0) | 216 (84.0) |
Born in Sweden | 266 (92.4) | 344 (90.1) | 302 (88.8) | 273 (85.3) | 216 (84.0) |
Education over 12 years | 179 (62.4) | 231 (60.8) | 174 (51.2) | 147 (46.1) | 111 (43.2) |
Sick leave previous year, mean (SD), days* | 2.5 (30.1) | 2.4 (27.2) | 6.0 (39.5) | 14.9 (67.0) | 27.8 (88.4) |
Disability pension previous year, mean (SD), days* | 6.8 (17.9) | 10.1 (34.1) | 18.8 (45.0) | 28.7 (62.7) | 49.7 (81.3) |
Comorbidity ≥1† | 15 (5.2) | 27 (7.1) | 41 (12.1) | 42 (13.1) | 36 (14.0) |
Depression diagnosis‡ | 1 (0.3) | 7 (1.8) | 12 (3.5) | 31 (9.7) | 35 (13.6) |
Anxiety diagnosis‡ | 5 (1.7) | 23 (6.0) | 23 (6.8) | 37 (11.6) | 50 (19.5) |
Other psychiatric comorbidities‡§ | 6 (2.1) | 19 (5.0) | 24 (7.1) | 22 (6.9) | 41 (16.0) |
Antidepressants treatment¶ | 8 (2.8) | 30 (7.9) | 37 (10.9) | 58 (18.1) | 66 (25.7) |
Anxiolytics treatment¶ | 6 (2.1) | 15 (3.9) | 7 (2.1) | 15 (4.7) | 20 (7.8) |
Symptomatic fatigue treatment¶ | 1 (0.3) | 2 (0.5) | 9 (2.6) | 6 (1.9) | 9 (3.5) |
Sleeping aids treatment¶ | 20 (6.9) | 36 (9.4) | 42 (12.4) | 38 (11.9) | 60 (23.3) |
Pain treatment¶ | 71 (24.7) | 96 (25.1) | 97 (28.5) | 115 (35.9) | 128 (49.8) |
DMT | |||||
Dimethyl fumarate | 61 (21.2) | 75 (19.6) | 65 (19.1) | 49 (15.3) | 46 (17.9) |
Fingolimod | 13 (4.5) | 20 (5.2) | 16 (4.7) | 7 (2.2) | 7 (2.7) |
Glatiramer acetate | 8 (2.8) | 13 (3.4) | 10 (2.9) | 18 (5.6) | 10 (3.9) |
Interferons** | 95 (33.0) | 106 (27.7) | 102 (30.0) | 93 (29.1) | 70 (27.2) |
Natalizumab | 30 (10.4) | 66 (17.3) | 50 (14.7) | 49 (15.3) | 42 (16.3) |
Rituximab | 77 (26.7) | 88 (23.0) | 89 (26.2) | 93 (29.1) | 73 (28.4) |
Teriflunomide | 4 (1.4) | 14 (3.7) | 8 (2.4) | 11 (3.4) | 9 (3.5) |
MS duration (years) | |||||
0–10 | 278 (96.9) | 373 (97.9) | 321 (94.7) | 308 (96.6) | 249 (97.3) |
>10 | 9 (3.1) | 8 (2.1) | 18 (5.3) | 11 (3.4) | 7 (2.7) |
Relapse previous year | 215 (74.7) | 252 (66.0) | 221 (65.0) | 204 (63.8) | 177 (68.9) |
New cerebral lesion previous year | 109 (44.3) | 171 (50.6) | 138 (45.2) | 141 (49.3) | 113 (49.3) |
FSMC total score, mean (SD) | 23.1 (5.5) | 34.7 (10.8) | 46.9 (11.5) | 56.4 (14.1) | 78.1 (13.6) |
EDSS score, median (IQR) | 1.0 (0.0–2.0) | 1.5 (1.0–2.0) | 2.0 (1.0–2.5) | 2.0 (1.0–2.5) | 2.5 (2.0–3.0) |
SDMT score, mean (SD) | 56.5 (12.1) | 55.7 (12.4) | 52.4 (10.8) | 51.1 (11.2) | 47.7 (11.5) |
MSIS-29 physical score, mean (SD) | 5.8 (9.9) | 9.5 (12.5) | 18.4 (16.9) | 23.4 (18.5) | 41.8 (21.3) |
MSIS-29 psychological score, mean (SD) | 18.1 (18.5) | 25.2 (19.5) | 35.4 (22.3) | 42.4 (21.4) | 58.8 (21.6) |
EQ-5D VAS score, mean (SD) | 82.5 (16.1) | 78.8 (17.2) | 69.4 (18.2) | 64.1 (18.2) | 51.1 (22.4) |
MS-symptoms inventory score, mean (SD) | 2.2 (2.0) | 5.6 (4.5) | 6.8 (4.4) | 9.8 (4.9) | 14.3 (4.4) |
*Restricted to participants 18–64 years old.
†Diagnosed within 5 years prior to DMT start according to the Charlson Comorbidity Index.
‡Diagnosed within 5 years prior to DMT start.
§All mental and behavioural disorders except depression and anxiety disorders.
¶Dispensed prescribed drugs within 1 year prior to DMT start.
**Interferon beta-1a, peginterferon beta-1a and interferon beta-1b.
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; EQ-5D VAS, EuroQol Visual Analogue Scale; FSMC, Fatigue Scale for Motor and Cognitive function; MS, multiple sclerosis; MSIS-29, MS Impact Scale; SDMT, Symbol Digit Modalities Test.